Page last updated: 2024-12-06

methylene bis(4-cyclohexylisocyanate)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methylene bis(4-cyclohexylisocyanate) (also known as MDI or H12MDI) is a diisocyanate used in the production of polyurethane foams, coatings, and elastomers. It is synthesized through the reaction of cyclohexylamine with phosgene. MDI is a highly reactive compound, and its polymerization can produce rigid or flexible foams with different properties. MDI-based polymers are used in a wide range of applications, including insulation, furniture, automotive parts, and construction materials. The high reactivity of MDI can pose a health hazard, as it can cause respiratory irritation and allergic reactions. Therefore, its handling requires appropriate safety precautions.'

methylene bis(4-cyclohexylisocyanate): used in manufacture of polyurethane foam; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dicyclohexylmethane-4,4'-diisocyanate : A diisocyanate consisting of dicyclohexylmethane with two isocyanate groups at the 4- and 4'-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21202
CHEMBL ID1878565
CHEBI ID53216
SCHEMBL ID22543
SCHEMBL ID5902920
SCHEMBL ID5903114
SCHEMBL ID8733246
SCHEMBL ID6318341
SCHEMBL ID10507329
SCHEMBL ID19751835
SCHEMBL ID22958492
SCHEMBL ID24783191
MeSH IDM0061489

Synonyms (96)

Synonym
4,4'-methylenedi(cyclohexyl isocyanate)
cyclohexane, 1,1'-methylenebis[4-isocyanato-
isocyanic acid, methylenedi-4,1-cyclohexylene ester
methylene bis-(4-cyclohexylisocyanate)
brn 2217800
hylene w
cp 99173
dicyclohexylmethane-4,4'-diisocyanate
dicyclohexylmethane 4,4'-diisocyanate
cyclohexane, 1,1'-methylenebis(4-isocyanato-
1,1-methylenebis(4-isocyanatocyclohexane) [diisocyanates]
nacconate h 12
methylene bis(4-cyclohexylisocyanate)
einecs 225-863-2
4,4'-methylenedicyclohexyl diisocyanate
methylenebis(4-cyclohexylisocyanate)
4,4'-diisocyanatodicyclohexylmethane
hsdb 7189
bis(4-isocyanatocyclohexyl)methane
5124-30-1
NCGC00164262-01
1,1'-methylenebis(4-isocyanatocyclohexane)
dicyclohexylmethane-4,4'-di-isocyanate
CHEBI:53216 ,
1-isocyanato-4-[(4-isocyanatocyclohexyl)methyl]cyclohexane
D2380
4,4'-methylenebis(cyclohexyl isocyanate)
AKOS000120188
z717id22kx ,
cyclohexane, 1,1'-methylenebis(4-isocyanato-, (trans,trans)-
unii-z717id22kx
4,4'-diisocyanatodicyclohexylmethane, trans,trans-
13622-90-7
28605-81-4
cyclohexane, 1,1'-methylenebis(isocyanato-
NCGC00255393-01
cas-5124-30-1
tox21_301473
dtxsid3027588 ,
dtxcid307588
1,1-methylene bis(4-isocyanatocyclohexane)
ec 225-863-2
4ct385m7k2 ,
unii-4ct385m7k2
1,1-methylenebis(4-isocyanatocyclohexane)
FT-0635549
EPITOPE ID:113239
cyclohexane, 1,1'-methylenebis[4-isocyanato-, (trans,trans)-
isocyanic acid, methylenedi-4,1-cyclohexylene ester, trans,trans-
trans,trans-4,4'-diisocyanatodicyclohexylmethane
trans-trans-methylenebis(4-cyclohexylisocyanate)
4,4'-diisocyanatodicyclohexylmethane, cis,cis-
p815vnf99i ,
4,4'-diisocyanatodicyclohexylmethane, cis,trans-
6y80aja84r ,
cis,cis-4,4'-diisocyanatodicyclohexylmethane
unii-6y80aja84r
isocyanic acid, methylenedi-4,1-cyclohexylene ester, cis,cis-
18937-00-3
cis-cis-methylene bis(4-cyclohexylisocyanate)
cis,trans-4,4'-diisocyanatodicyclohexylmethane
cyclohexane, 1,1'-methylenebis(4-isocyanato-, (cis(cis))-
isocyanic acid, methylenedi-4,1-cyclohexylene ester, cis,trans-
unii-p815vnf99i
cyclohexane, 1,1'-methylenebis(4-isocyanato-, (cis(trans))-
17901-48-3
cis-trans-methylene bis(4-cyclohexylisocyanate)
SCHEMBL22543
SCHEMBL5902920
SCHEMBL5903114
4,4'-methylenebis-(cyclohexyl isocyanate)
KORSJDCBLAPZEQ-UHFFFAOYSA-N
4,4'-diisocyanato dicyclohexylmethane
methylene-bis-(4-cyclohexyl isocyanate)
SCHEMBL8733246
SCHEMBL6318341
CHEMBL1878565
methylene-bis(4-cyclohexylisocyanate)
SCHEMBL10507329
F2191-0303
dicyclohexylmethane-4,4'-diiso cyanate
mfcd00015405
hmdi, analytical standard
(trans,trans)-1,1'-methylenebis[4-isocyanatocyclohexane]
DTXSID30891145
dicyclohexyl-methane-4,4'-diisocyanate
SCHEMBL19751835
Q1562648
Q27295091
Q27286344
Q27265708
BS-42301
SCHEMBL22958492
156515-75-2
F87466
SCHEMBL24783191

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In mice, as well as in guinea pigs, a dose-response relationship was apparent between the sensitizing dose and both severity of response and number of animals responding."( Use of dose-response data to compare the skin sensitizing abilities of dicyclohexylmethane-4,4'-diisocyanate and picryl chloride in two animal species.
Karol, MH; Stadler, JC, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
diisocyanateAn isocyanate compound containing two isocyanate functional groups. Manufactured for reaction with polyols in the production of polyurethanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.61130.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency43.27710.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency50.11870.000221.22318,912.5098AID588515
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency48.96620.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.31860.003041.611522,387.1992AID1159552; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency54.48270.005428.02631,258.9301AID1346982
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency48.966219.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.07940.010039.53711,122.0200AID588547
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (29.63)18.7374
1990's4 (14.81)18.2507
2000's7 (25.93)29.6817
2010's8 (29.63)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.69 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies3 (10.71%)4.05%
Observational0 (0.00%)0.25%
Other24 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]